Senhong Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Senhong Lee has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Francis Yi Xing Lai
Department of Dermatology, Monash Health, Clayton, VIC, Australia
5 shared publications - James Gaston
Department of Dermatology Royal Children's Hospital Melbourne Parkville Victoria Australia
4 shared publications Francis Yi Xing Lai
Faculty of Medicine, Nursing and Health Sciences, School of Clinical Sciences, Monash Health, Monash University, Clayton, VIC, Australia
3 shared publicationsIan Simpson
Department of Anatomical Pathology Monash Health Clayton Victoria Australia
3 shared publications- Andrew Maxwell
Royal Children's Hospital Melbourne Melbourne Victoria Australia
2 shared publications - Anna Antony
School of Clinical Sciences, Monash University, Wellington Road, Clayton, VIC 3168, Australia
2 shared publications
Latest Publications
- 7 October 2026
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
Granuloma Faciale
- 7 October 2026
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
Granuloma Faciale
- Open Access
- 7 October 2026
- Published by Wiley in Pediatric Dermatology
Erythematous Pustular Plaques in a Child
- 7 October 2026
- Published by Wiley in Pediatric Dermatology
Open AccessErythematous Pustular Plaques in a Child
- 23 September 2026
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
Acquired Cutix Laxa
- 23 September 2026
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
Acquired Cutix Laxa
- Open Access
- 14 September 2026
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
Type VI Pityriasis Rubra Pilaris: A Systematic Review
- 14 September 2026
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
Open AccessType VI Pityriasis Rubra Pilaris: A Systematic Review
- 26 July 2026
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 67 (7)
Patient Acceptability, Perceptions and Concerns Regarding Artificial Intelligence Scribes in Outpatient Dermatology Clinics
This cross‐sectional survey assessed patient acceptability, perceptions and concerns regarding ambient artificial intelligence (AI) scribes in an outpatient dermatology clinic. Most patients reported comfort with AI scribe use (82.1%) despite limited prior exposure, although over half expressed concerns. These findings highlight the need for transparent, patient‐centred implementation strategies and tailored discussions addressing patient concerns.
- 26 July 2026
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 67 (7)
Patient Acceptability, Perceptions and Concerns Regarding Artificial Intelligence Scribes in Outpatient Dermatology Clinics
This cross‐sectional survey assessed patient acceptability, perceptions and concerns regarding ambient artificial intelligence (AI) scribes in an outpatient dermatology clinic. Most patients reported comfort with AI scribe use (82.1%) despite limited prior exposure, although over half expressed concerns. These findings highlight the need for transparent, patient‐centred implementation strategies and tailored discussions addressing patient concerns.
- Open Access
- 10 July 2026
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
Acneiform eruption with deucravacitinib: a systematic review and meta-analysis
Background: Deucravacitinib, an oral selective tyrosine kinase 2 (TYK2) inhibitor, is an effective treatment for chronic plaque psoriasis. Its use is expanding to treat other autoinflammatory conditions; however, acneiform eruptions have been increasingly reported. Objectives: To explore this, we conducted a systematic review and meta-analysis to quantify the incidence of acneiform eruptions associated with deucravacitinib and compare odds ratios (ORs) vs. placebo, including exploratory analyses by dose and indication. Methods: The CENTRAL, Embase and MEDLINE databases were searched for interventional and observational studies. The primary outcome was the incidence of acneiform eruption (including acne, folliculitis, dermatitis acneiform and rosacea). A random-effects meta-analysis was performed to estimate pooled proportions and ORs. Results: Of 672 records screened, 14 studies met the inclusion criteria, representing 5280 patients treated with deucravacitinib. Overall, 467/5280 (8.8%) patients developed an acneiform eruption (acne, 71.3%; folliculitis, 23.3%; dermatitis acneiform, 3.2%; and rosacea, 2.1%). Across eight placebo-controlled studies, the pooled incidence was 6.4% [95% confidence interval (CI) 0.05–0.09; I2 = 74.9%]. Events occurred in 145/2539 (5.7%) patients on deucravacitinib vs. 9/1070 (0.8%) in controls (pooled OR, 4.56; 95% CI 2.28–9.12; I2 = 9.4%). Discontinuations for acneiform events were uncommon (n = 7/3317; 0.2%). Dose-specific and indication-specific analyses suggested higher odds of acneiform events at higher total daily doses and in indications such as psoriasis and inflammatory bowel disease. Conclusions: Acneiform eruptions are a frequent cutaneous adverse event with deucravacitinib and occur markedly more often than with placebo, yet rarely lead to discontinuation.
- 10 July 2026
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
Open AccessAcneiform eruption with deucravacitinib: a systematic review and meta-analysis
Background: Deucravacitinib, an oral selective tyrosine kinase 2 (TYK2) inhibitor, is an effective treatment for chronic plaque psoriasis. Its use is expanding to treat other autoinflammatory conditions; however, acneiform eruptions have been increasingly reported. Objectives: To explore this, we conducted a systematic review and meta-analysis to quantify the incidence of acneiform eruptions associated with deucravacitinib and compare odds ratios (ORs) vs. placebo, including exploratory analyses by dose and indication. Methods: The CENTRAL, Embase and MEDLINE databases were searched for interventional and observational studies. The primary outcome was the incidence of acneiform eruption (including acne, folliculitis, dermatitis acneiform and rosacea). A random-effects meta-analysis was performed to estimate pooled proportions and ORs. Results: Of 672 records screened, 14 studies met the inclusion criteria, representing 5280 patients treated with deucravacitinib. Overall, 467/5280 (8.8%) patients developed an acneiform eruption (acne, 71.3%; folliculitis, 23.3%; dermatitis acneiform, 3.2%; and rosacea, 2.1%). Across eight placebo-controlled studies, the pooled incidence was 6.4% [95% confidence interval (CI) 0.05–0.09; I2 = 74.9%]. Events occurred in 145/2539 (5.7%) patients on deucravacitinib vs. 9/1070 (0.8%) in controls (pooled OR, 4.56; 95% CI 2.28–9.12; I2 = 9.4%). Discontinuations for acneiform events were uncommon (n = 7/3317; 0.2%). Dose-specific and indication-specific analyses suggested higher odds of acneiform events at higher total daily doses and in indications such as psoriasis and inflammatory bowel disease. Conclusions: Acneiform eruptions are a frequent cutaneous adverse event with deucravacitinib and occur markedly more often than with placebo, yet rarely lead to discontinuation.
- Open Access
- 20 April 2026
- Published by Oxford University Press (OUP) in Skin Health and Disease
- Vol. 6 (3) , 329-331
A rare case of acute generalized exanthematous pustulosis-like Sweet syndrome
Acute generalized exanthematous pustulosis (AGEP) is a pustular drug eruption characterized by superficial pustules, commonly caused by β-lactam antibiotics. Management of AGEP involves discontinuation of the offending medication and supportive therapy with topical corticosteroids and analgesia, given the self-limiting nature of this condition. In contrast, Sweet syndrome (SS), or acute febrile neutrophilic dermatosis, is characterized by the sudden onset of painful, inflamed skin lesions associated with fever. SS typically requires investigations for associated conditions and systemic corticosteroids, resulting in rapid improvement within days. We present a case of AGEP-like SS, initially diagnosed clinically as AGEP in the setting of intravenous antibiotic use, where the patient deteriorated, despite antibiotics being stopped. Skin biopsy revealed papillary dermal oedema with neutrophilic infiltrate, and scattered histiocytoid cells and eosinophils, resulting in a revised diagnosis of AGEP-like SS. The patient was started on oral corticosteroids and achieved complete resolution of disease within 2 days. This case highlights AGEP-like SS as an important differential diagnosis in patients presenting with AGEP-like eruptions, as the management of AGEP and SS is different.
- 20 April 2026
- Published by Oxford University Press (OUP) in Skin Health and Disease
- Vol. 6 (3) , 329-331
Open AccessA rare case of acute generalized exanthematous pustulosis-like Sweet syndrome
Acute generalized exanthematous pustulosis (AGEP) is a pustular drug eruption characterized by superficial pustules, commonly caused by β-lactam antibiotics. Management of AGEP involves discontinuation of the offending medication and supportive therapy with topical corticosteroids and analgesia, given the self-limiting nature of this condition. In contrast, Sweet syndrome (SS), or acute febrile neutrophilic dermatosis, is characterized by the sudden onset of painful, inflamed skin lesions associated with fever. SS typically requires investigations for associated conditions and systemic corticosteroids, resulting in rapid improvement within days. We present a case of AGEP-like SS, initially diagnosed clinically as AGEP in the setting of intravenous antibiotic use, where the patient deteriorated, despite antibiotics being stopped. Skin biopsy revealed papillary dermal oedema with neutrophilic infiltrate, and scattered histiocytoid cells and eosinophils, resulting in a revised diagnosis of AGEP-like SS. The patient was started on oral corticosteroids and achieved complete resolution of disease within 2 days. This case highlights AGEP-like SS as an important differential diagnosis in patients presenting with AGEP-like eruptions, as the management of AGEP and SS is different.
- 25 February 2026
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
Vaccination-Induced Pityriasis Rubra Pilaris: A Systematic Review
- 25 February 2026
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
Vaccination-Induced Pityriasis Rubra Pilaris: A Systematic Review
- 19 November 2025
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 30 (1)
Cutaneous Metastasis Presenting as Wolf’s Isotopic Response
- 19 November 2025
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 30 (1)
Cutaneous Metastasis Presenting as Wolf’s Isotopic Response
- 24 October 2025
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 51 (3) , 374-380
Paraneoplastic pityriasis rubra pilaris: a systematic review
Background: Paraneoplastic pityriasis rubra pilaris (PRP) is a rare and poorly defined chronic inflammatory skin condition. Recognition of its potential association with cancer is crucial to facilitate timely diagnosis and treatment. Objectives: To summarize published literature on paraneoplastic PRP, with a focus on associated cancer types, latency periods, treatment outcomes and resolution following oncological management. Methods: A literature review was conducted following PRISMA guidelines using the MEDLINE, Embase, Cochrane Library and Web of Science databases. Search terms used were ‘pityriasis rubra pilaris’, ‘malignancy’, ‘cancer’ and ‘paraneoplastic’, and inclusion criteria were adults diagnosed with both cancer and probable paraneoplastic PRP. Two authors independently reviewed the titles and abstracts of all identified papers before the full text of potentially relevant studies was retrieved for further analysis. Results: From 978 articles screened, 22 studies describing 23 adult patients were included. Solid tumours were implicated in 83% of cases (n = 19/23), with lung cancer the most common of these (n = 7/19, 37%). The median latency from PRP onset to cancer diagnosis was 9 weeks [interquartile range (IQR): 0.4–25.0]. Among 17 patients experiencing complete or partial resolution of PRP following treatment for their cancer, complete resolution occurred in 65% (n = 11/17), typically within a median of 11 weeks (IQR: 6.8–22.8). The overall mortality rate in evaluable cases was 16% (n = 3/19). Conclusions: In this systematic review, paraneoplastic PRP was associated with multiple types of cancer, both solid and haematological. Cancer screening should be considered in cases of atypical or treatment-refractory PRP. Further prospective studies are required to define predictive features and optimize diagnostic approaches.
- 24 October 2025
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 51 (3) , 374-380
Paraneoplastic pityriasis rubra pilaris: a systematic review
Background: Paraneoplastic pityriasis rubra pilaris (PRP) is a rare and poorly defined chronic inflammatory skin condition. Recognition of its potential association with cancer is crucial to facilitate timely diagnosis and treatment. Objectives: To summarize published literature on paraneoplastic PRP, with a focus on associated cancer types, latency periods, treatment outcomes and resolution following oncological management. Methods: A literature review was conducted following PRISMA guidelines using the MEDLINE, Embase, Cochrane Library and Web of Science databases. Search terms used were ‘pityriasis rubra pilaris’, ‘malignancy’, ‘cancer’ and ‘paraneoplastic’, and inclusion criteria were adults diagnosed with both cancer and probable paraneoplastic PRP. Two authors independently reviewed the titles and abstracts of all identified papers before the full text of potentially relevant studies was retrieved for further analysis. Results: From 978 articles screened, 22 studies describing 23 adult patients were included. Solid tumours were implicated in 83% of cases (n = 19/23), with lung cancer the most common of these (n = 7/19, 37%). The median latency from PRP onset to cancer diagnosis was 9 weeks [interquartile range (IQR): 0.4–25.0]. Among 17 patients experiencing complete or partial resolution of PRP following treatment for their cancer, complete resolution occurred in 65% (n = 11/17), typically within a median of 11 weeks (IQR: 6.8–22.8). The overall mortality rate in evaluable cases was 16% (n = 3/19). Conclusions: In this systematic review, paraneoplastic PRP was associated with multiple types of cancer, both solid and haematological. Cancer screening should be considered in cases of atypical or treatment-refractory PRP. Further prospective studies are required to define predictive features and optimize diagnostic approaches.